{"id":"adjunctive-zonisamide","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Somnolence"},{"rate":"10-15","effect":"Ataxia"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Anorexia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"1-4","effect":"Nephrolithiasis (kidney stones)"},{"rate":"1-3","effect":"Oligohydrosis (decreased sweating)"}]},"_chembl":{"chemblId":"CHEMBL750","moleculeType":"Small molecule","molecularWeight":"212.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zonisamide blocks voltage-gated sodium and T-type calcium channels, reducing repetitive neuronal firing. It also inhibits carbonic anhydrase, which may contribute to its anticonvulsant effects. When used adjunctively, it enhances seizure control in combination with other antiepileptic drugs.","oneSentence":"Zonisamide is an anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade and carbonic anhydrase inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:17.421Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive therapy for partial seizures in epilepsy"},{"name":"Adjunctive therapy for generalized tonic-clonic seizures"}]},"trialDetails":[{"nctId":"NCT01830868","phase":"","title":"A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-03","conditions":"Partial Onset Seizures","enrollment":104},{"nctId":"NCT03636958","phase":"NA","title":"Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy","status":"WITHDRAWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2021-02-15","conditions":"Refractory Epilepsy","enrollment":""},{"nctId":"NCT01140867","phase":"PHASE4","title":"Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2008-02-29","conditions":"Epilepsy","enrollment":121},{"nctId":"NCT01713946","phase":"PHASE3","title":"A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04-29","conditions":"Tuberous Sclerosis Complex-associated Refractory Seizures","enrollment":366},{"nctId":"NCT00692003","phase":"PHASE3","title":"Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures","status":"TERMINATED","sponsor":"Eisai Limited","startDate":"2008-08-01","conditions":"Epilepsy","enrollment":21},{"nctId":"NCT01136954","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Extension Study)","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2008-07","conditions":"Partial Seizures","enrollment":144},{"nctId":"NCT00693017","phase":"PHASE3","title":"Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy","status":"TERMINATED","sponsor":"Eisai Limited","startDate":"2008-06","conditions":"Epilepsy","enrollment":10},{"nctId":"NCT00047567","phase":"PHASE4","title":"Open-label Adjunctive Zonisamide for Bipolar Disorder","status":"TERMINATED","sponsor":"Elan Pharmaceuticals","startDate":"2002-07","conditions":"Bipolar Disorders","enrollment":20},{"nctId":"NCT00713622","phase":"PHASE4","title":"Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2008-06","conditions":"Epilepsy","enrollment":2},{"nctId":"NCT01630057","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2009-09","conditions":"Partial Seizures","enrollment":200},{"nctId":"NCT01283256","phase":"","title":"A Study to Evaluate the Safety and Efficacy of Zonisamide an Antiepileptic Drug as Monotherapy or Adjunctive Therapy in Treatment of Adult Patients With Partial, Generalized or Combined Seizures.","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-01","conditions":"Partial, Generalized and Combined Seizures","enrollment":655},{"nctId":"NCT01587339","phase":"","title":"Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Epilepsy","enrollment":6498},{"nctId":"NCT00659958","phase":"PHASE4","title":"ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-04","conditions":"Epilepsy","enrollment":32},{"nctId":"NCT00566254","phase":"PHASE3","title":"Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-12","conditions":"Epilepsy; Paediatric Partial Onset Seizures","enrollment":207}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Adjunctive Zonisamide","genericName":"Adjunctive Zonisamide","companyName":"Eisai Inc.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zonisamide is an anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade and carbonic anhydrase inhibition. Used for Adjunctive therapy for partial seizures in epilepsy, Adjunctive therapy for generalized tonic-clonic seizures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}